Therefore, combining RT with IO or immune-stimulatory agents which act to reprogramme myeloid cells and drive increased T cell infiltration into tumours (e.g., TLR agonists, anti-CD40 mAb, anti-OX40 mAb) may be required to overcome this immunosuppressive TME and improve tumour control and survival [109,110]. Here, TNFRSF4 is linked to neoplasm.